EU-QPPV registration and local pharmacovigilance contacts

2:39

In the European Union, ensuring the safety of human pharmaceutical products requires strict compliance with pharmacovigilance regulations. At the heart of this system is the Qualified Person Responsible for Pharmacovigilance (QPPV).

This role, established under Article 23 of Regulation (EC) No 726/2004, is critical to maintaining a compliant pharmacovigilance system for products marketed in the EU.

What is a(n) (EU-)QPPV?

The EU-QPPV is a mandatory role for any holder of a marketing authorization for human-use drugs. This individual, typically an employee of the pharmaceutical company, is responsible for ensuring that pharmacovigilance systems operate effectively and comply with EU safety regulations.

When submitting a marketing authorization application, companies must provide:

A description of their pharmacovigilance system, outlining how they will monitor product safety during real-world use.

Proof of a QPPV’s appointment, ensuring the role is permanently and continuously available.

As the regulation states:

"The holder of an authorization for a medicinal product for human use granted in accordance with the provisions of this Regulation shall have permanently and continuously at their disposal an appropriately qualified person responsible for pharmacovigilance."

How to register an EU-QPPV

Navigating the registration process for a QPPV or transitioning to a new QPPV can seem complex, but the European Medicines Agency (EMA) provides clear guidance.

Steps to register or change a QPPV:

New Registration
Companies must submit detailed information about the candidate's qualifications, experience, and responsibilities to demonstrate their capability for the role.

Change of QPPV
Seamlessly transitioning to a new QPPV involves adhering to specific EMA procedures to maintain regulatory compliance.

Detailed guidance on these processes is available on the EMA website: EMA QPPV Registration Guidance.

Local pharmacovigilance contacts in EU member states

In addition to the EU-QPPV, some EU member states require local pharmacovigilance contacts to bridge communication between companies and national health authorities. These contacts ensure that country-specific pharmacovigilance requirements are fulfilled.

Key considerations for local pharmacovigilance contacts:

Requirement by Country: Not all EU member states require local pharmacovigilance contacts. Detailed requirements for each country are provided by the EMA: Local Contact Requirements.

Steps to Nominate: In countries where local contacts are needed, companies must follow the specified steps, including providing detailed information about the individual’s qualifications and responsibilities.

Why choose QbD Group for QPPV and local contact support?

At QbD Group, we have extensive experience in supporting pharmaceutical companies with QPPV registration and the nomination of local pharmacovigilance contacts. With our team of experts, you can:

navigate country-specific requirements for local pharmacovigilance contacts.

anticipate and address regulatory challenges with comprehensive solutions.

Our experience and guidance ensure you’re always prepared for compliance audits and inspections.

Conclusion: compliance made simple

Compliance with EU pharmacovigilance regulations starts with appointing a qualified QPPV and, where necessary, nominating local pharmacovigilance contacts. These steps are critical to protecting patient safety and maintaining regulatory approval for your products.

At QbD Group, we simplify this process. From registration to regulatory guidance, we’re here to help you every step of the way.

Ready to streamline your pharmacovigilance compliance? Contact QbD Group today to schedule a consultation with our experts.

EU-QPPV registration and local pharmacovigilance contacts: what you need to know

What is a(n) (EU-)QPPV?

How to register an EU-QPPV

Local pharmacovigilance contacts in EU member states

Why choose QbD Group for QPPV and local contact support?

Conclusion: compliance made simple

Stay ahead in life sciences

Discover more expert content

Post-Market Surveillance (PMS) and Post-Market Clinical Follow-Up (PMCF) under the MDR: Ensuring safety and performance

What Makes Usability Testing Crucial for Near-Patient and Self-Testing Devices under IVDR?

When does Annex XIV apply in Performance Studies, and what key documentation is needed for compliance?

How to define your Clinical Performance Strategy?